Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
UBS
Medtronic
Covington
Merck

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,549,940

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,549,940 protect, and when does it expire?

Patent 9,549,940 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.

Summary for Patent: 9,549,940
Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:15/259,841
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,549,940
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 9,549,940

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up Y USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up Y USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up Y USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
Deloitte
Express Scripts
US Army
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.